Previous Close | 0.9500 |
Open | 0.9215 |
Bid | 0.9357 x 900 |
Ask | 0.9600 x 1800 |
Day's Range | 0.8800 - 0.9599 |
52 Week Range | 0.8200 - 5.4400 |
Volume | |
Avg. Volume | 156,044 |
Market Cap | 40.998M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4580 |
Earnings Date | Jun 20, 2022 - Jun 24, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.04 |
Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3 remains on track to start before year-end A conference call to discuss the results scheduled for Wednesday May 18th at 1:00 PM Eastern Time LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study
LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022.
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Spring into Action: VIRTUAL begins on Monday, May 16th, 2022, with a Biotech Discovery Day.